Finance

Lists
TSHA:NASDAQ
Taysha Gene Therapies Inc
$5.60
+0.54%
(+0.030) 1D
$5.75
+2.68% (+0.15)
After hours
Closed: Sep 4, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TSHA...
Open
$5.52
High
$5.61
Low
$5.42
Mkt. cap
1.82B
Avg. vol.
2.51M
Volume
2.11M
52-wk high
$7.30
52-wk low
$2.72
EPS
-$0.41
Beta
1.19
Shares outstanding
325.83M
No. of employees
99
Open
$5.52
High
$5.61
Low
$5.42
Mkt. cap
1.82B
Avg. vol.
2.51M
Volume
2.11M
52-wk high
$7.30
52-wk low
$2.72
EPS
-$0.41
Beta
1.19
Shares outstanding
325.83M
No. of employees
99
News stories
From web sources and news partners
About Taysha Gene Therapies Inc
CEO-
Employees99
Founded2019
HeadquartersDallas, Texas, United States
SectorBiotechnology
Analyst ratings
Based on 11 analysts giving stock ratings to TSHA in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for TSHA in the last 3 months.
Highest
Current $5.60
$19.00 (+239.29%)
Average
$13.70 (+144.64%)
Lowest
$11.00 (+96.43%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
08/14/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$19.00
+239.3%
08/11/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$13.00
+132.1%
08/11/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$17.00
+203.6%
08/11/2026
Biren Amin
Piper Sandler
Buy
Maintained
$12.00
+114.3%
08/12/2026
Unknown Analyst
Wells Fargo
Buy
Reiterated
$11.00
+96.4%
08/12/2026
Gil Blum
Needham
Buy
Maintained
$12.00
+114.3%
08/12/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$14.00
+150%
06/30/2026
Jack Allen
Robert W. Baird
Buy
Maintained
$15.00
+167.9%
06/30/2026
Keith Tapper CFA
BMO Capital
Buy
Maintained
$14.00
+150%
06/23/2026
Unknown Analyst
Jefferies
Buy
Maintained
$13.00
+132.1%
06/23/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
$11.00
+96.4%
06/23/2026
Unknown Analyst
Bank of America Securities
Buy
Reiterated
$9.00
+60.7%
05/08/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$11.00
+96.4%
05/07/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$12.00
+114.3%
05/06/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.13 / -$0.11
-20.93%miss
Revenue / Est. (USD)
- / 618.18K
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
5.48M
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
25.74M
24.95M
33.81M
38.64M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.28M
8.83M
9.68M
12.15M
Operating expense
34.02M
33.78M
43.49M
47.35M
Total operating expenses
34.02M
33.78M
43.49M
47.35M
Operating income
-34.02M
-28.30M
-43.49M
-47.35M
Other non operating income
-1.86M
3.76M
-31.00K
-88.00K
EBT including unusual items
-32.73M
-27.85M
-42.41M
-46.64M
EBT excluding unusual items
-32.73M
-21.68M
-40.94M
-45.12M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-3.43M
Net income
-32.73M
-27.85M
-42.41M
-46.64M
Net profit margin
-
-507.77%
-
-
Earnings per share
-0.09
-0.07
-0.11
-0.13
Interest and investment income
3.17M
2.87M
2.59M
2.32M
Interest expense
-15.00K
-12.00K
-9.00K
-6.00K
Net interest expenses
3.15M
2.86M
2.58M
2.32M
Depreciation and amortization charges
-
-
-
-
EBITDA
-33.74M
-28.00M
-43.19M
-47.06M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google apps